{
  "industry": "chemistry",
  "stage": "seed",
  "pageType": "metrics-benchmarks",
  "slug": "/investor-questions/chemistry/seed/metrics-benchmarks/",
  "ctaText": "Create your PitchChat room",
  "dataOrigin": "editorial",
  "sourceId": "editorial-chemistry-seed",
  "sourceNotes": "Editorial guidance prepared by Pitchchat; not sourced from user submissions.",
  "sourceTags": [
    "editorial",
    "pitchchat-guidance"
  ],
  "title": "Chemistry Seed fundraising metrics benchmarks",
  "summary": "Seed-stage biotech metrics focus on scientific validation and development progress rather than commercial metrics. Investors evaluate data quality, IP position, and team capability. These benchmarks help demonstrate you've de-risked the science enough for institutional investment. Pitchchat keeps fundraising metrics investor-ready in one room.",
  "metrics": [
    {
      "label": "Development Stage",
      "value": "Discovery to IND-enabling",
      "note": "Preclinical or IND-enabling stages most common for seed. Later stage commands premium valuation.",
      "source": "ICIS Chemicals Resources (https://www.icis.com/explore/resources/chemicals/)"
    },
    {
      "label": "Lead Candidates",
      "value": "1-3 programs",
      "note": "Focused pipeline preferred. Lead program should be clearly prioritized with backup compounds.",
      "source": "ICIS Chemicals Resources (https://www.icis.com/explore/resources/chemicals/)"
    },
    {
      "label": "In-Vivo Data",
      "value": "Proof-of-concept in relevant models",
      "note": "Animal model data supporting mechanism. Efficacy and preliminary safety signals valuable.",
      "source": "ICIS Chemicals Resources (https://www.icis.com/explore/resources/chemicals/)"
    },
    {
      "label": "Patents Filed",
      "value": "2-5 applications",
      "note": "Composition-of-matter priority. Geographic coverage in key markets (US, EU, Japan, China).",
      "source": "ICIS Chemicals Resources (https://www.icis.com/explore/resources/chemicals/)"
    },
    {
      "label": "Freedom-to-Operate",
      "value": "Preliminary analysis complete",
      "note": "FTO analysis identifying potential blocking patents. Clearance strategy if issues identified.",
      "source": "ICIS Chemicals Resources (https://www.icis.com/explore/resources/chemicals/)"
    },
    {
      "label": "Regulatory Interactions",
      "value": "Pre-IND meeting planned or completed",
      "note": "FDA engagement demonstrates pathway clarity. Type B meeting feedback highly valuable.",
      "source": "ICIS Chemicals Resources (https://www.icis.com/explore/resources/chemicals/)"
    },
    {
      "label": "CMO Identified",
      "value": "Manufacturing partner selected",
      "note": "Contract manufacturer identified for scale-up. Process development timeline understood.",
      "source": "ICIS Chemicals Resources (https://www.icis.com/explore/resources/chemicals/)"
    },
    {
      "label": "Key Opinion Leader Support",
      "value": "2-3 engaged advisors",
      "note": "KOLs validating science and clinical approach. Active involvement, not just names on website.",
      "source": "ICIS Chemicals Resources (https://www.icis.com/explore/resources/chemicals/)"
    },
    {
      "label": "Non-Dilutive Funding",
      "value": "$500K - $2M",
      "note": "SBIR/STTR grants, foundation funding, or pharma collaboration. Extends runway and validates science.",
      "source": "ICIS Chemicals Resources (https://www.icis.com/explore/resources/chemicals/)"
    },
    {
      "label": "Team Size",
      "value": "5-15 people",
      "note": "Core R&D team with drug development experience. CSO/CMO-caliber leadership.",
      "source": "ICIS Chemicals Resources (https://www.icis.com/explore/resources/chemicals/)"
    }
  ]
}